Precision BioSciences, Inc. Common Stock

DTIL Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
DTIL Income Statement
DTIL Balance Sheet
DTIL Cash Flow
Congress Trading

Recent trades of DTIL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
DTIL Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
DTIL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
DTIL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by DTIL's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene Jun. 11, 2024
  • Patent Title: Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene May. 28, 2024
  • Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Dec. 26, 2023
  • Patent Title: Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome Oct. 17, 2023
  • Patent Title: Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene Oct. 17, 2023
  • Patent Title: Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene Sep. 12, 2023
  • Patent Title: Engineered meganucleases specific for recognition sequences in the pcsk9 gene Jun. 20, 2023
  • Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Sep. 27, 2022
  • Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Jul. 12, 2022
  • Patent Title: Co-stimulatory domains for use in genetically-modified cells Mar. 29, 2022
  • Patent Title: Engineered nucleases useful for treatment of hemophilia a Mar. 22, 2022
  • Patent Title: Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome Mar. 15, 2022
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Mar. 08, 2022
  • Patent Title: Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene Mar. 08, 2022
  • Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Nov. 30, 2021
  • Patent Title: Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome Oct. 12, 2021
  • Patent Title: Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene Jul. 06, 2021
  • Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) May. 18, 2021
  • Patent Title: Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome Dec. 01, 2020
  • Patent Title: Co-stimulatory domains for use in genetically-modified cells Oct. 13, 2020
  • Patent Title: Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene Oct. 13, 2020
  • Patent Title: Treatment of retinitis pigmentosa using engineered meganucleases Sep. 01, 2020
  • Patent Title: Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof Aug. 18, 2020
  • Patent Title: Self-limiting viral vectors encoding nucleases May. 26, 2020
  • Patent Title: Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome May. 26, 2020
  • Patent Title: Recognition sequences for i-crei-derived meganucleases and uses thereof May. 14, 2019
  • Patent Title: Recognition sequences for i-crei-derived meganucleases and uses thereof Apr. 30, 2019
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Oct. 09, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Oct. 09, 2018
  • Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences Aug. 07, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Jun. 12, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Jun. 12, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene May. 15, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Apr. 24, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Apr. 24, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Feb. 13, 2018
  • Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Feb. 13, 2018
  • Patent Title: Methods and products for producing engineered mammalian cell lines with amplified transgenes Nov. 21, 2017
  • Patent Title: Recognition sequences for i-crei-derived meganucleases and uses thereof Jun. 20, 2017
  • Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences Sep. 06, 2016
  • Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences May. 17, 2016
  • Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences May. 21, 2013
  • Patent Title: Rationally-designed meganuclease variants of lig-34 and i-crei for maize genome engineering Dec. 25, 2012
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of DTIL in WallStreetBets Daily Discussion

DTIL News

Recent insights relating to DTIL

CNBC Recommendations

Recent picks made for DTIL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in DTIL

DTIL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view DTIL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top